Kedudukan dalam Saham
#17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Harga Saham
$0.8502
Disegerakkan terakhir: 2026-09-01
Perubahan (1 hari)
-10.96%
Perubahan (1 tahun)
-17.46%
Perdagangan Invivyd, Inc. (IVVD)
Harga IVVD dengan permodalan pasaran b
Modal pasaran bagi Invivyd, Inc.(IVVD)
Modal Pasaran: $250.47M
Sehingga September 2026, Invivyd, Inc. mempunyai modal pasaran sebanyak $250.47M. Ini menjadikan Invivyd, Inc. syarikat ke-17262nd paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Invivyd, Inc. dari 2021 hingga 2026
IVVD berbanding dengan 5 teratas yang paling popular stocks
| Harga IVVD |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.260T
|
+2,099,755.20%
|
|
|
|
|
$4.779T
|
+1,907,688.73%
|
|
|
|
|
$4.017T
|
+1,603,550.29%
|
|
|
|
|
$3.719T
|
+1,484,803.25%
|
|
|
|
|
$2.734T
|
+1,091,522.35%
|
